![](/getmedia/7ec00afc-3372-40d3-9055-1543cbf769ee/Platinum-Small.png?width=499&height=436&ext=.png)
![](/getmedia/7004d860-4426-486f-8549-9b96c79267c6/trade-mark.png?width=492&height=154&ext=.png)
The median 5-year survival for adult AML is less than 30% and one-third of children with AML relapse due to treatment resistance, with only 30% of relapsed patients surviving their disease.
Survival starts with science. Your donation will keep this project going.
Resistance to treatment is thus a major challenge within the AML field and there is an urgent need to develop more effective and safer treatments for AML.
Altered metabolism plays a key role in cancer progression and resistance to treatment, making it an attractive therapeutic target. This research team recently showed that acute myeloid leukaemia (AML) cells are addicted to a metabolic enzyme called NAMPT, and that blocking NAMPT kills AML cells and also makes them more sensitive to standard of care drugs. By adding a newly developed NAMPT inhibitor to standard of care treatment, this project can pave the way towards a more effective treatment of poor outcome adult and paediatric AML.
*Learn about Cancer Australia's Priority-driven Collaborative Cancer Research Scheme.
Dr Klaartje Somers
Children’s Cancer Institute
$181,559 January 2023 to December 2025
$381,559
$563,118